ALS Investment Fund

VectorY Therapeutics is a gene therapy company founded in August 2020 at the Amsterdam Science Park. The company focuses on developing innovative therapeutics, particularly vectorized antibodies, targeting central nervous system (CNS) and somatic disorders, with a special emphasis on muscle diseases. By integrating the strengths of antibodies and gene therapy, VectorY aims to create long-lasting therapeutic solutions for significant health challenges that lack adequate treatment options. Their platform is designed to facilitate scalable manufacturing processes that effectively target specific cell types and sub-cellular compartments while minimizing the risks associated with host immune response. This approach allows healthcare professionals to address critical areas of unmet medical need effectively.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.